Cipla
VC Fund
Mumbai, India
Cipla is a drug manufacturing company that focuses on a variety of pharmaceutical products.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Cipla invests in
Stages Cipla invests in
Countries Cipla invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 3 (38%)
- Biotechnology 2 (25%)
- Medical Device 2 (25%)
- Pharmaceutical 2 (25%)
- Sales 1 (13%)
Stage
- Corporate Round 4 (50%)
- Series A 1 (13%)
- Series B 1 (13%)
Country
- India 3 (38%)
- Germany 1 (13%)
- United States 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Naina Kidwai
Non-Executive Member of the Board of Directors
|
Non-Executive Member of the Board of Directors | Total investments: 0 | Find email | |
|
Sahil Kumar
Manager Corporate Strategy
|
Manager Corporate Strategy | Total investments: 0 | Find email | |
Vikram Sudarsan
Strategy Head - Cipla New Ventures - Cipla USA
|
Strategy Head - Cipla New Ventures - Cipla USA | Total investments: 1 | Find email | |
Samina Vaziralli
Global Head - Strategy & New Ventures
|
Global Head - Strategy & New Ventures | Total investments: 1 | Find email | |
Y. K Hamied
Founder & Chairman
|
Founder & Chairman | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
iCaltech Innovations
|
Caltech Innovations designs and develops medical devices. Antlia is a forced oscillation technique-based system for the clinical evaluation of the respiratory system under tidal breathing conditions. FOT is a clinically proven technology that is an alternative to conventional spirometry. | $579.5K / Corporate Round / Jul 21, 2025 | |
GoApptiv
|
GoApptiv offers end-to-end go-to-market solutions to pharmaceutical companies in India. Our proprietary data analytics tools combined with a network of distribution partners allows us to access these markets in the most cost effective and efficient way possible. HeathTech | Data Analytics | Phygital | $5M / Corporate Round / Dec 14, 2023 | |
ETHRIS
|
ETHRIS develops mRNA therapeutics with a focus on respiratory diseases and vaccines. ETHRIS possesses an enabling LNP delivery and mRNA modification platform for transcript Therapies. SNIM®RNAis a first-in-class biopharmaceutical which provide a compelling alternative for recombinant protein or gene therapies. SNIM®RNAs encode therapeutic proteinsto be produced in the patient‘s body and overcome short duration effects of recombinant proteins. SNIM®RNA Transcript Therapy is a new option for a broad variety of diseases, either acquired or genetically predetermined, lifestyle- or age-related, rare or frequent. | $16M / Corporate Round / Dec 29, 2022 | |
|
GoApptiv
|
GoApptiv offers end-to-end go-to-market solutions to pharmaceutical companies in India. Our proprietary data analytics tools combined with a network of distribution partners allows us to access these markets in the most cost effective and efficient way possible. HeathTech | Data Analytics | Phygital | $15M / Series A / Jun 28, 2022 | |
|
GoApptiv
|
GoApptiv offers end-to-end go-to-market solutions to pharmaceutical companies in India. Our proprietary data analytics tools combined with a network of distribution partners allows us to access these markets in the most cost effective and efficient way possible. HeathTech | Data Analytics | Phygital | $3.3M / Corporate Round / Jun 27, 2022 | |
|
GoApptiv
|
GoApptiv offers end-to-end go-to-market solutions to pharmaceutical companies in India. Our proprietary data analytics tools combined with a network of distribution partners allows us to access these markets in the most cost effective and efficient way possible. HeathTech | Data Analytics | Phygital | $1.2M / Corporate Round / Jun 10, 2020 | |
Wellthy Therapeutics
|
Wellthy Therapeutics design and deploy clinically validated behavioral interventions for chronic disease management, and are pioneering Digital Therapeutics, an entirely new category of medicine to address the chronic health epidemic in South Asia at scale. | $1.5M / Corporate Round / Feb 18, 2019 | |
Chase Pharmaceuticals
|
Chase Pharmaceuticals (CPC) is engaged in the identification and clinical development of medically improved, commercially promising, treatments for central nervous system (CNS) disease. The Company was incorporated in 2007 to link emerging technical opportunities in the basic neurosciences to the expanding medical needs of those withneuropsychiatric disease. Operations thus focus on selecting product candidates to license-in, adding value by advancing towards global registration, and licensing-out to commercial partners. There success reflects an exceptional ability to select promising drug candidates, intimate knowledge of the development process as well as our ability to devise the most efficient path to regulatory approval.Since inception, CPC has sought to develop novel compounds that could improve the treatment of AD and related neurodegenerative disorders. Alzheimer’s disease constitutes the largest unmet medical need in neuropsychiatry. No emerging therapies have clearly demonstrated the potential to fulfill this medical need. Symptoms include an increasing loss of memory and other cognitive functions later combined with a variety of neuropsychiatric and behavioral disturbances. Progression is relentless, typically leading to death within 10 to 15 years. AD is now recognized as the third leading killer in the U.S. It is estimated that the 37 million afflicted worldwide cost society over $600 billion annually. As the population ages, this burden will rapidly climb to unsustainable levels. Although US sales of Alzheimer’s disease medications last year topped $4.7 billion, none of the current treatments improve symptoms more than marginally. Moreover, tolerability is poor, dose titration prolonged, and dropout rates high.Chase founders have invented and patented a unique combination of proven, currently marketed pharmaceuticals that we believe will benefit the symptomatic treatment of AD. | $21M / Series B / May 12, 2014 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Cipla invest in?
Cipla invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Corporate Round and Series A stage. Most of the 8 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Cipla?
Public channels for Cipla include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cipla?
The team at Cipla includes Naina Kidwai (Non-Executive Member of the Board of Directors), Sahil Kumar (Manager Corporate Strategy) and Vikram Sudarsan (Strategy Head - Cipla New Ventures - Cipla USA). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
